Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves’ disease

Jiaqi Li, MD, Huiwen Tan, MD, Juan Huang, MD, Dan Luo, MD, Ying Tang, MD, Ruichao Yu, MD, Hui Huang, MD.

Abstract
Rationale: Thyrotropin-secreting adenoma (TSHoma) is rare. Even though the thyrotoxicosis is mild in patients with TSHoma, it is still a rare cause of arrhythmia, ignore of mild dysfunction of thyroid function of TSHoma can lead to the delayed diagnosis of pituitary tumor or leading to recurring of complications. Graves’ disease is an auto-immune endocrinological disorder. Association of TSHoma and Graves’s disease is extremely rare. Coexistence of these two diseases makes the diagnosis and treatment complicated.

Patient concerns: This patient was a 55-year-old man who had been referred to the department of endocrinology and metabolism of the West China Hospital due to recurrent atrial fibrillation (AF) and thyrotoxicosis.

Diagnoses: Examinations revealed pituitary thyrotropin-secreting macroadenoma with Graves’ disease.

Interventions: We conducted transsphenoidal surgery. Thyrozol was used to treat the recurrence of Graves’ disease after pituitary surgery.

Outcomes: The TSHoma was successfully cured, and recurrent Graves’ disease was controlled very well.

Lessons: The association of TSHoma and Graves’ disease is extremely rare. Even though the clinical features of thyrotoxicosis are milder in patients with TSHoma, thyroid function tests are still important clinical assessment of patients with AF, which is an arrhythmia associated with hyperthyroidism. TSHoma is a rare cause of thyrotoxicosis; however, ignoring of the mild dysfunction caused by TSHoma can lead to the delayed diagnosis of pituitary tumors or to recurring complications of TSHoma.

Abbreviations: AF = atrial fibrillation, BMI = body mass index, FT3 = free triiodothyronine, FT4 = free thyroxine, ICAM-1 = intercellular adhesion molecule-1, MRI = magnetic resonance imaging, PRL = prolactin, RR = relative risk, SITSH = syndrome of inappropriate secretion of TSH, TgAb = thyroglobulin antibodies, TPOAb = thyroperoxidase antibodies, TRAb = thyrotropin receptor antibody, TSH = thyroid stimulating hormone, TSHoma = TSH-secreting pituitary adenomas.

Keywords: Graves’ disease, recurrent atrial fibrillation, thyrotropin-secreting adenoma

1. Introduction
Thyrotropin-producing pituitary adenoma (TSHoma) is a rare disease, representing only 1% of all pituitary tumors.[1] The clinical features of thyrotoxicosis are milder in patients with TSHoma, possibly due to a reduction in the biological activity of pituitary-secreted TSH. Even though thyroid function tests to exclude hyperthyroidism are regular clinical assessments of patients with atrial fibrillation (AF), which is an arrhythmia associated with hyperthyroidism,[2] TSHoma is such a rare cause of thyrotoxicosis that the mild thyroid dysfunction caused by TSHoma may be ignored, leading to the delayed diagnosis of pituitary tumors or to recurring complications of TSHoma. Graves’ disease is an autoimmune endocrinological disorder. The association of TSHoma with Graves’ disease is extremely rare. The coexistence of these 2 diseases makes diagnosis and treatment complicated. Here, we report a case of a patient with Graves’ disease with recurrent AF induced by TSHoma who experienced a relapse of Graves’ disease 1 year after pituitary surgery.

2. Case report
This patient was a 55-year-old man who had consulted at a local hospital for incidentally discovered AF. After being treated with amiodarone for a year, his electrocardiogram (ECG) remained abnormal. Then, he was transferred to the cardiovascular department of our hospital. He had no symptoms such as chest congestion, dizziness, or fatigue, nor did he exhibit symptoms of metabolic syndromes such as tachycardia, trembling, or hyperhidrosis. Radiofrequency ablation was performed to treat his AF. The ECG recovered, but the laboratory tests showed TSH 8.9 mU/L...
(RR, 0.27–4.2), FT3 6.61 pmol/L (RR, 3.6–7.5), and FT4 33.47 pmol/L (RR, 12–22). He ignored the suggestion to consult an endocrinologist. Three months later, the AF recurred, so he received radiofrequency ablation again. Nine months after the patient was discharged from the cardiovascular department, he was referred to our outpatient division for tachycardia, tremors, and thermophobia. At that time, the hormonal examination implied thyrotoxicosis, with a positive result for the TSH receptor antibody (FT3 34.34 pmol/L, FT4 > 100 pmol/L, TSH 0.755 mU/L, TRAb 15.28 IU/L). After administration of thyrozol 10 mg twice a day for 4 months, his symptoms resolved, and his thyroid hormone levels returned to within normal ranges; however, his TSH level was markedly increased. It was suggested to the patient that he should consult an endocrinologist for further examination of the inappropriate secretion of TSH due to central hyperthyroidism. On physical examination at admission, the patient was 172.0 cm tall and weighed 73 kg (body mass index, 24.7 kg/m²). His blood pressure was 135/80 mm Hg, and his pulse was 75 beats/min. The thyroid gland was diffusely enlarged, and ultrasonography of the thyroid revealed a rich vascular supply with a nodule located in the left lobe. Fine needle inspiration biopsy suggested the nodule was benign. The computer perimetry suggested a defective visual field. Magnetic resonance imaging (MRI) of the sella region revealed a pituitary tumor measuring 2.3 × 1.7 × 2.2 cm³ in the sella, involving the cavernous sinuses and extending into the suprasellar cistern (Fig. 1). Based on these data, we diagnosed the patient with TSH-producing pituitary macroadenoma and central hyperthyroidism. One week after diagnosis, in May 2014, total resection of the pituitary macroadenoma was performed through transsphenoidal neurosurgery. Upon immunohistochemical examination, the resected pituitary adenoma cells exhibited positive staining with the TSH and PRL antibodies, and the percentage of positive Ki-67 was less than 2%, suggesting that the tumor was benign (Fig. 2). After surgery, his TSH levels and thyroid hormone levels remained within the normal ranges. His serum thyroid hormone levels increased beyond the normal ranges 1 year later (TSH 0.223, FT3 11.36, FT4 36.36), although no residual tumor was apparent on the MRI. Positive results were obtained for TRAb, and both TgAb and TPOAb were elevated beyond their normal ranges (TRAb 5.62 IU/L, TgAb 32.79 IU/L, TPOAb 14.13 IU/L). The patient was administered thyrozol 10 mg/day, and his thyroid function tests remained clinically acceptable during 3 years of follow-up. Repeated pituitary MRIs showed a possible mass in the pituitary, suggesting tumor recurrence. In addition, recent ultrasonography showed that the thyroid nodule remained the same size.

3. Discussion
TSHomas are usually large tumors with neurological features, and they generally cause enlargement of the thyroid gland. Despite this fact, however, most patients present mild signs of thyrotoxicosis, possibly due to a reduction in the biological activity of the secreted TSH. However, our case illustrates that although uncommon and thought to present with mild

Figure 1. A pituitary tumor measuring 2.3 × 1.7 × 2.2 cm³ in the sella, involving the cavernous sinuses and extending into the suprasellar cistern.
In our case, antithyroid medication was chosen to treat the Graves’ disease, failed to normalize the TT4, TT3, and TSH levels, resulting instead in the progression of TSHoma. Administration of antithyroid medication may increase the risk of TSHoma progression due to the inappropriate elevated TSH level after antithyroid therapy. We reviewed the history of this patient and discovered the previous abnormal results of thyroid function tests and the suspected diagnosis of TSHoma at the first presentation of AF.

The treatment of TSHoma with Graves’ disease is complicated. In the previous reported cases, antithyroid medication, which was chosen first to treat the Graves’ disease, failed to normalize the TT4, TT3, and TSH levels, resulting instead in the progression of the TSHoma. Administration of antithyroid medication may increase the risk of TSHoma progression due to the positive feedback system. In our case, antithyroid medication was initially administered; however, the TSHoma was successfully treated by endoscopic transsphenoidal neurosurgery. The patient’s TT3, TT4, and TSH levels decreased gradually and eventually normalized. However, unfortunately, his TT4, TT3, and TRAb levels increased again and his TSH level decreased 1 year after surgery. At that time, antithyroid medication was administered again without concern for the progression of the TSHoma because the successful removal of the TSHoma also removed the potential risk of tumor enlargement.

The relationship between TSHoma and Graves’ disease is controversial. TSH plays an important role in the maintenance of the normal physiology and immunomodulatory gene expression of the thyroid gland. Therefore, the continuous abnormal hypersecretion of TSH can produce increased levels of antithyroidic antibodies, causing Graves’ disease. These observations suggest that the normalization of TSH secretion by treating TSHomas may improve Graves’ hyperthyroidism. However, the cause of postoperative recurrence of Graves’ disease in our patient is unclear.

Some reports have shown that Graves’ disease subsequently occurred after TSHoma removal. They suggested that TSH can upregulate the TSH receptor at the mRNA level in cultured human thyroid cells,[19] and it can also suppress the expression of interferon α-induced Fas,[13] intercellular adhesion molecule (ICAM)-1,[16] and class II transactivators on the thyroid cell surface.[17] Therefore, the previous studies suspected that Fas-mediated apoptosis of thyroid cells can be induced by the rapid reduction in TSH levels that occur after tumor resection, which may activate autoimmune responses against the thyroid gland, leading to the occurrence of Graves’ disease after surgery. Hence, the surgical treatment of TSHoma may be considered the first choice in patients with TSHoma associated with Graves’ disease to prevent the enlargement of the tumor induced by antithyroidism therapy.

4. Conclusion

We report an extremely rare case of a TSHoma associated with Graves’ disease in a male patient who initially presented with recurrent AF. This case highlights the need to evaluate thyroid function in all patients presenting with AF, and treatment of TSHoma associated with Graves’ disease should be carefully taken into account to avoid the potential risk of tumor progression due to treatment. In addition, physicians should also pay attention to the development of Graves’ disease not only during the progression of TSHoma but also after TSHoma has been treated.

Acknowledgments

We acknowledge the patient and his family for allowing us to use his medical documentation and information. We acknowledge Dr. Yi Wei of the West China Hospital of Sichuan University for performing the MRI scan.

Author contributions

Conceptualization: Jiaqi Li, Hui Huang.
Data curation: Jiaqi Li, Huiwen Tan, Dan Luo, Ying Tang.
Formal analysis: Juan Huang, Ruichao Yu.
Funding acquisition: Jiaqi Li.
Investigation: Jiaqi Li.
Methodology: Jiaqi Li.
Resources: Huiwen Tan, Dan Luo, Ying Tang, Juan Huang.
Software: Dan Luo, Ying Tang.
Supervision: Ying Tang.
Writing – original draft: Jiaqi Li.
Writing – review & editing: Ruichao Yu, Hui Huang.

References

[1] Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003;148:433–42.
[2] Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007;167:928–34.
[3] George JT, Thow JC, Matthews B, et al. Atrial fibrillation associated with a thyroid stimulating hormone-secreting adenoma of the pituitary gland leading to a presentation of acute cardiac decompensation: a case report. J Med Case Rep 2008;2:1–4.
[4] Kamoi K, Mitsuma T, Sato H, et al. Hyperthyroidism caused by a pituitary thyrotropin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves’ disease in a middle-aged woman. Acta Endocrinol (Copenh) 1985;110:373–82.
[5] Arai N, Inaba M, Ichiyu T, et al. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves’ disease: a case report. J Med Case Rep 2017;11:9.
[6] Koriyama N, Nakazaki M, Hashiguchi H, et al. Thyrotropin-producing pituitary adenoma associated with Graves’ disease. Eur J Endocrinol 2004;151:87–94.
[7] Ogawa Y, Tominaga T. Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves’ disease: a case report. J Med Case Rep 2013;7:27.
[8] Ramos-Levi AM, Moreno JC, Alvarez-Escola C, et al. Coexistence of thyroid hormone resistance syndrome, pituitary adenoma and Graves’ disease. Endocrinol Nutr 2016;63:139–41.
[9] Beck-Peccoz P, Lania A, Beckers A, et al. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2013;2:76–82.
[10] Sandler R. Recurrent hyperthyroidism in an acromegalic patient previously treated with proton beam irradiation: Graves’ disease as probable etiology based on follow-up observations. J Clin Endocrinol Metab 1976;42:163–8.
[11] Lee MT, Wang CY. Concomitant Graves hyperthyroidism with thyrotropin-secreting pituitary adenoma. South Med J 2010;103:347–8.
[12] Kamoun M, D’Herbomez M, Lemaire C, et al. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and Graves’ hyperthyroidism. Eur Thyroid J 2014;3:60–4.
[13] Ogawa Y, Tominaga T. A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment. J Neurooncol 2008;87:91–5.
[14] Huber GK, Weinstein SP, Graves PN, et al. The positive regulation of human thyrotropin (TSH) receptor messenger ribonucleic acid by recombinant human TSH is at the intranuclear level. Endocrinology 1992;130:2858–64.
[15] Kawakami A, Eguchi K, Matsuoka N, et al. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 1996;137:3163–9.
[16] Chung J, Park ES, Kim D, et al. Thyrotropin modulates interferon-gamma-mediated intercellular adhesion molecule-1 gene expression by inhibiting Janus kinase-1 and signal transducer and activator of transcription-1 activation in thyroid cells. Endocrinology 2000;141:2090–7.
[17] Kim H, Suh JM, Hwang ES, et al. Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling. J Immunol 2003;171:616–27.